Alex Brown was appointed the Chief Operating Officer of Convergent Therapeutics in August 2021. Prior to joining Convergent, Mr. Brown was the Head of New Product Planning, Global Oncology, at Sanofi responsible for the commercial readiness of the company’s early-stage oncology pipeline. Before that, he served in several positions of increasing responsibility at EMD Serono (a Merck KGaA subsidiary). Most recently, as Senior Director, Global Commercial Oncology, BAVENCIO® (avelumab), Mr. Brown was a founding member of the Merck KGaA-Pfizer immune-oncology alliance and responsible for the first commercialization of BAVENCIO® in Merkle Cell carcinoma.  Earlier in his career, Mr. Brown supported the commercialization of ICLUSIG® (ponatinib) and ALUNBRIG® (brigatinib) at ARIAD Pharmaceuticals, Inc. and earlier at Sanofi, was responsible for global development operations in support of the launch and life-cycle management of JEVTANA® (cabazitaxel) in prostate cancer.

Mr. Brown earned his Bachelor of Science in medical microbiology and immunology from the University of Wisconsin-Madison and his Master of Business Administration from Carnegie-Mellon University.